Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Cancers, Free Full-Text

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial - The Lancet Oncology

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity

Cancers, Free Full-Text

Immune Checkpoint Inhibitors for Brain Metastases: A Primer for Neurosurgeons. - Document - Gale OneFile: Health and Medicine

Full article: Efficacy and safety of the combined use of ipilimumab and nivolumab for melanoma patients with brain metastases: a systematic review and meta-analysis

Nivolumab With Ipilimumab May Negate Need for Whole Brain Radiotherapy in Melanoma With Brain Metastases - Cancer Therapy Advisor

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study - ScienceDirect

Nivolumab + Ipilimumab Shows Efficacy for Untreated Brain Mets

Updated Data for First-Line Immunotherapy Combinations Reinforce Their Value in Metastatic Melanoma